FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2756934266> ?p ?o ?g. }

• W2756934266 endingPage "479" @default.
• W2756934266 startingPage "477" @default.
• W2756934266 abstract "Psoriasis is an immune-mediated disease characterized by formation of well-demarcated plaques with silver scale. Drugs such as cyclosporine and methotrexate can have deleterious side effects; however, biologic immune modifying agents now provide a safer alternative for psoriasis. Ustekinumab, an interleukin (IL) 12/23 inhibitor, is one such agent and is approved by The US Food and Drug Administration for the treatment of moderate to severe chronic plaque psoriasis. Vitiligo is an acquired autoimmune disorder resulting in depigmented patches of skin. Alopecia areata (AA) is another autoimmune disease that results in nonscarring hair loss. Current therapies for both conditions are limited, typically involving topical, intralesional, or systemic steroids.1Park K. Jang W.S. Son I.P. et al.Combination therapy with cyclosporine and psoralen plus ultraviolet a in the patients with severe alopecia areata: a retrospective study with a self-controlled design.Ann Dermatol. 2013; 25: 12-16Crossref PubMed Scopus (19) Google Scholar Because these traditional therapies are not sufficiently efficacious, new modalities including laser and biologic agents are being explored.2Guttman-Yassky E. Ungar B. Noda S. et al.Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism.J Allergy Clin Immunol. 2016; 137: 301-304Abstract Full Text Full Text PDF PubMed Scopus (61) Google Scholar A 39-year-old South Asian woman weighing 94 kg presented to our clinic in February 2016 with a several-year history of moderate generalized plaque psoriasis. In addition to psoriasis, she had a 1-year history of nonsegmental vitiligo of the face, scalp, and neck, and a 2-year history of patchy alopecia of the scalp. Her medical history was significant for asthma and penicillin allergy. She had no associated joint pain or personal history of other autoimmune disorder. Her family history was, however, significant for hypothyroidism. On physical examination, the patient had well-demarcated, erythematous, scaly plaques covering approximately 10% of her body surface area. She was also noted to have 3 well-demarcated, depigmented patches ranging in size from 2 to 4 cm on the face to 5 cm on the back of her scalp. Finally, the patient had significantly decreased hair density with several round patches of nonscarring hair loss ranging from 2 to 4 cm in diameter. These findings were consistent with 3 separate diagnoses: moderate chronic plaque psoriasis, vitiligo, and AA. In the past, the patient had been treated with etanercept for her psoriasis with no improvement. For her vitiligo, she had received intralesional triamcinolone injections with only minimal improvement. For her AA, she had received intramuscular vitamin B complex injections, also with a poor clinical response. After explaining the benefits and risk, the patient consented to treatment with ustekinumab 90 mg subcutaneous injection, initially administered at 0 and 4 weeks. Subsequent doses were administered every 8 weeks. Dose selection was based on our experience with AA in a published study where 90 mg of ustekinumab every 8 weeks proved effective.2Guttman-Yassky E. Ungar B. Noda S. et al.Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism.J Allergy Clin Immunol. 2016; 137: 301-304Abstract Full Text Full Text PDF PubMed Scopus (61) Google Scholar Because of a lack of established protocols in the published literature for either condition, we opted for what worked for AA. No other adjuvant medications were used with ustekinumab. The patient showed significant improvement in erythema and scaling of psoriatic lesions by week 8 and complete resolution with body surface area 0% by week 16. In addition to the excellent response seen with her psoriasis, the patient showed impressive improvement in vitiligo and AA lesions of the scalp (Fig 1). The vitiligo on her face and neck also improved. At week 20, hair density had visibly increased and repigmented macules were noted around the hair follicles in previously depigmented patches (Fig 2). The patient tolerated ustekinumab without adverse effects, and laboratory monitoring revealed no abnormalities.Fig 2Patient at week 0 of ustekinumab therapy with visible scattered alopecia patches and markedly decreased overall hair density (A) compared to week 20 (B) of ustekinumab therapy with visible regrowth and increased hair density.View Large Image Figure ViewerDownload Hi-res image Download (PPT) Over the last few years, the number of therapeutic options for the treatment of plaque psoriasis has increased dramatically. Secondary to discoveries in the immunopathogenesis of the disease, different molecular targets, including tumor necrosis factor–alpha, ILs-12 and -23, IL-17, and others, have paved the way for targeted biologic therapies. On the contrary, vitiligo and AA have seen little success thus far in efficacious therapeutic options. Classically, these 2 entities have been treated with topical, intralesional, or systemic steroids. Recently, however, advances toward the development of biologic therapies for these 2 autoimmune diseases have been made. The Janus kinase (JAK) pathway has been explored as a potential target for treatment of both vitiligo and AA. In several case reports, 1 open-label study, and 1 retrospective study, JAK inhibitors were shown to be effective for inducing hair regrowth in patients with AA. The efficacy of JAK inhibitors for AA is currently being investigated in clinical trials. Similarly, JAK inhibitors show promise for the treatment of vitiligo.3Samadi A. Ahmad Nasrollahi S. Hashemi A. Nassiri-Kashani M. Firooz A. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of the literature.J Dermatolog Treat. 2017; ([Epub ahead of print]): 1-11https://doi.org/10.1080/09546634.2016.1277179Crossref PubMed Scopus (34) Google Scholar In a recently published report, a vitiligo patient quickly improved after receiving ruxolitinib, a drug that inhibits JAKs, which are important for immune cell signaling. The patient's facial pigmentation improved from <1% to >50% in just 4 to 5 months.4Harris J. Rashighi M. Nguyen N. et al.Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA).J Am Acad Dermatol. 2016; 74: 370-371Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar While the pathogenesis of vitiligo and AA is not straightforward and likely involves a combination of genetic susceptibility and environmental factors, it is evident that proinflammatory cytokines play a role and can perhaps be targeted with the same therapies that have seen great success in psoriasis. The role of IL-23 in the immunopathogenesis of autoimmune disorders is complex. Genomic association studies have shown ILs-12 and -23 to be implicated in the pathway responsible for psoriasis; therefore, the 2 have been targets for drug development. These studies resulted in the discovery of ustekinumab, an IL-12/23 antagonist that has proven to be highly efficacious in treating plaque psoriasis. IL-23 is the cytokine responsible for proliferation and survival of TH17 cells, which represent an important T-cell subset in autoimmune disease beyond psoriasis. These disorders include Crohn's disease, vitiligo, and AA.5Stockinger B. Veldhoen M. Differentiation and function of Th17 T cells.Curr Opin Immunol. 2007; 19: 281Crossref PubMed Scopus (584) Google Scholar, 6Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis.J Invest Dermatol. 2008; 128: 1064Abstract Full Text Full Text PDF PubMed Scopus (135) Google Scholar, 7Tesmer L.A. Lundy S.K. Sarkar S. Fox D.A. Th17 cells in human disease.Immunol Rev. 2008; 223: 87Crossref PubMed Scopus (835) Google Scholar As expected, our patient's psoriatic lesions responded dramatically to ustekinumab. However, marked improvement was also noted in her vitiligo and AA. It is the striking increase in hair density and notable repigmentation that suggest IL-12/23 blockade is a promising therapeutic strategy for patients with these autoimmune conditions as well as psoriasis. It should be noted that the complex pathophysiology of these conditions means that ustekinumab may not have such robust response in all patients with vitiligo and AA. Two published studies had conflicting results on ustekinumab effectiveness in vitiligo and AA.8Méry-Bossard L. Bagny K. Chaby G. et al.New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory disease.J Eur Acad Dermatol Venerol. 2017; 31: 181-186Crossref PubMed Scopus (44) Google Scholar, 9Slowińska M. Kardynal A. Warszawik O. Czuwara J. Rudnicka L. Alopecia areata developing parallel to improvement of psoriasis during ustekinumab therapy.J Dermatol Case Rep. 2010; 4: 15-17Crossref PubMed Scopus (33) Google Scholar However, the success seen in this patient with concomitant psoriasis, vitiligo, and AA should prompt consideration of ustekinumab in those for whom vitiligo and AA have proven refractory to other available treatments. Additional prospective studies will be required to determine the long-term safety and efficacy of ustekinumab in these populations." @default.
• W2756934266 created "2017-10-06" @default.
• W2756934266 creator A5022111346 @default.
• W2756934266 creator A5024365532 @default.
• W2756934266 creator A5065568518 @default.
• W2756934266 creator A5074169689 @default.
• W2756934266 creator A5087588819 @default.
• W2756934266 date "2017-11-01" @default.
• W2756934266 modified "2023-10-18" @default.
• W2756934266 title "Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata" @default.
• W2756934266 cites W1969629598 @default.
• W2756934266 cites W1976591271 @default.
• W2756934266 cites W1980911992 @default.
• W2756934266 cites W2017987372 @default.
• W2756934266 cites W2048681505 @default.
• W2756934266 cites W2199733448 @default.
• W2756934266 cites W2205406616 @default.
• W2756934266 cites W2421547005 @default.
• W2756934266 cites W2566974850 @default.
• W2756934266 doi "https://doi.org/10.1016/j.jdcr.2017.07.009" @default.
• W2756934266 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5614637" @default.
• W2756934266 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28971137" @default.
• W2756934266 hasPublicationYear "2017" @default.
• W2756934266 type Work @default.
• W2756934266 sameAs 2756934266 @default.
• W2756934266 citedByCount "18" @default.
• W2756934266 countsByYear W27569342662018 @default.
• W2756934266 countsByYear W27569342662019 @default.
• W2756934266 countsByYear W27569342662020 @default.
• W2756934266 countsByYear W27569342662021 @default.
• W2756934266 countsByYear W27569342662022 @default.
• W2756934266 countsByYear W27569342662023 @default.
• W2756934266 crossrefType "journal-article" @default.
• W2756934266 hasAuthorship W2756934266A5022111346 @default.
• W2756934266 hasAuthorship W2756934266A5024365532 @default.
• W2756934266 hasAuthorship W2756934266A5065568518 @default.
• W2756934266 hasAuthorship W2756934266A5074169689 @default.
• W2756934266 hasAuthorship W2756934266A5087588819 @default.
• W2756934266 hasBestOaLocation W27569342661 @default.
• W2756934266 hasConcept C126322002 @default.
• W2756934266 hasConcept C16005928 @default.
• W2756934266 hasConcept C2777524370 @default.
• W2756934266 hasConcept C2778975655 @default.
• W2756934266 hasConcept C2779134260 @default.
• W2756934266 hasConcept C2779384505 @default.
• W2756934266 hasConcept C2779980618 @default.
• W2756934266 hasConcept C2780132546 @default.
• W2756934266 hasConcept C2780200183 @default.
• W2756934266 hasConcept C2780564577 @default.
• W2756934266 hasConcept C71924100 @default.
• W2756934266 hasConceptScore W2756934266C126322002 @default.
• W2756934266 hasConceptScore W2756934266C16005928 @default.
• W2756934266 hasConceptScore W2756934266C2777524370 @default.
• W2756934266 hasConceptScore W2756934266C2778975655 @default.
• W2756934266 hasConceptScore W2756934266C2779134260 @default.
• W2756934266 hasConceptScore W2756934266C2779384505 @default.
• W2756934266 hasConceptScore W2756934266C2779980618 @default.
• W2756934266 hasConceptScore W2756934266C2780132546 @default.
• W2756934266 hasConceptScore W2756934266C2780200183 @default.
• W2756934266 hasConceptScore W2756934266C2780564577 @default.
• W2756934266 hasConceptScore W2756934266C71924100 @default.
• W2756934266 hasIssue "6" @default.
• W2756934266 hasLocation W27569342661 @default.
• W2756934266 hasLocation W27569342662 @default.
• W2756934266 hasLocation W27569342663 @default.
• W2756934266 hasLocation W27569342664 @default.
• W2756934266 hasLocation W27569342665 @default.
• W2756934266 hasOpenAccess W2756934266 @default.
• W2756934266 hasPrimaryLocation W27569342661 @default.
• W2756934266 hasRelatedWork W1492474251 @default.
• W2756934266 hasRelatedWork W161749209 @default.
• W2756934266 hasRelatedWork W1993845216 @default.
• W2756934266 hasRelatedWork W2105984679 @default.
• W2756934266 hasRelatedWork W2436773801 @default.
• W2756934266 hasRelatedWork W2756934266 @default.
• W2756934266 hasRelatedWork W2766455916 @default.
• W2756934266 hasRelatedWork W3008532238 @default.
• W2756934266 hasRelatedWork W2955017652 @default.
• W2756934266 hasRelatedWork W3120353753 @default.
• W2756934266 hasVolume "3" @default.
• W2756934266 isParatext "false" @default.
• W2756934266 isRetracted "false" @default.
• W2756934266 magId "2756934266" @default.
• W2756934266 workType "article" @default.